MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the first ...

U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the ...

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company ...

For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over the same period last year. EPS came in at $2.07, compared to $1.40 in the year-ago quarter. The reported ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK), while reporting higher first-quarter earnings, above market estimates, on Thursday raised its fiscal 2024 adjusted earnings and sales view. In ...

MRK has a GLP-1 candidate in the clinical trial phase 2, efinopegdutide, with it outperforming semaglutide for weight loss and liver fat content moderation. However, with the stock currently ...

is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth over the last year and a ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

Merck MRK will report first-quarter 2024 results on ... Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that the company is excessively ...